Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
Highlights
– In a small cohort of patients with metastatic melanoma (n=14 evaluable), low‑dose subcutaneous IL‑2 after lymphodepletion and TIL infusion produced clinical outcomes comparable to high‑dose intravenous IL‑2 when followed by pembrolizumab.
– Overall response rates were low in both arms; one durable ongoing partial response (>76 months) occurred in the low‑dose arm.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.